1.Recent updates on extranodal NK/T-cell lymphoma.
Korean Journal of Medicine 2009;77(5):565-570
Extranodal NK/T-cell lymphoma (ENKL) is a rare subtype of NHL (Non-Hodgkin lymphoma]. It occurs mostly in the nasal and paranal areas. Most of the cases are presented stage I/II. International prognostic index (IPI) can predict the outcome. However, better prognostic model is available such as NKIPI. Because of high expression of p-glycoprotein, ENKL is refractory to chemotherapy. Early stage disease can be bestly treated with concurrent chemoradiation. For advanced stage disease, new clinical trials are now being conducted.
Lymphoma
;
P-Glycoprotein
2.Overexpression of P-glycoprotein in gastric cancer by immunohistochemical staining method.
Hyun Cheol CHUNG ; Ho Young LIM ; Eun Hee KOH ; Joo Hang KIM ; Jae Kyung ROH ; Jin Sik MIN ; Joung Ju CHOI ; Jung Kyu YOUN ; Byung Soo KIM ; Kyi Beom LEE
Journal of the Korean Cancer Association 1991;23(3):485-494
No abstract available.
P-Glycoprotein*
;
Stomach Neoplasms*
3.The expression of P-glycoprotein and the DNA content as a prognostic indicator in breast cancers.
Jeoung Won BAE ; Cheung Wung WHANG
Journal of the Korean Surgical Society 1993;45(3):343-352
No abstract available.
Breast*
;
DNA*
;
P-Glycoprotein*
4.Acute monocytic leukemia with P-glycoprotein expression.
Hae Kyung LEE ; Kyung Ja HAN ; Kyo Young LEE ; Sang In SHIM ; Sun Woo KIM
Korean Journal of Clinical Pathology 1991;11(2):409-412
No abstract available.
Leukemia, Monocytic, Acute*
;
P-Glycoprotein*
5.Does 3-O-Methyldopa(3-OMD) Inhibit the Binding of Levodopa to Plasma Protein.
Jin Woo BAE ; Sebastian HARDER
Korean Journal of Psychopharmacology 1999;10(2):180-184
OBJECTIVE: We determined the influence of 3-OMD in the protein binding of levodopa to estimate the effect of 3-OMD on the penetration of levodopa into brain. METHOD: P-glycoprotein in the brain may serve to limit drug penetration into the brain. Because it is not available as an experimental substance, but has similar binding properties with alpha 1 acid glycoprotein(AGP), we used AGP in this study. Additionally, we used blood plasma to see the affinity of plasma binding of levodopa. The final concentration of chemicals used in this study were 125, 250, 500, 1000, 2000, 4000 microgram/l for levodopa and 0, 1250, 5000, 10,000 microgram/l for 3-OMD, 1 mg/l for AGP. The free fraction of levodopa in blood plasma and AGP were separated by ultrafiltration method and determined by beta-counter, respectively. RESULTS: We found that levodopa did not bind with AGP, but only 22-24% from 125 microgram/l to 4000 microgram/l of it bound with blood plasma. The addition of 3-OMD to the blood plasma did not significantly change the binding of levodopa. CONCLUSIONS: We can conclude that 3-OMD does not influence the penetration of levodopa into brain. These small amount of the binding does not expect to influence to other drugs on the binding with plasma.
Brain
;
Drug Interactions
;
Levodopa*
;
P-Glycoprotein
;
Plasma*
;
Protein Binding
;
Ultrafiltration
6.Expression of p-glycoprotein on human bladder transitional cell carcinoma.
Sung Koo JANG ; Joo Hee LEE ; Joon Woong SON ; Choong Hyun LEE ; Jin Il KIM ; Soo Yong CHAE
Journal of the Korean Cancer Association 1993;25(2):268-275
No abstract available.
Carcinoma, Transitional Cell*
;
Humans*
;
P-Glycoprotein*
;
Urinary Bladder*
7.Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.
Journal of Korean Medical Science 2017;32(9):1542-1547
Oseltamivir is a substrate of P-glycoprotein, an efflux drug transporter encoded by ABCB1. The objective of this study was to assess the role of ABCB1 (c.1236C>T, c.2677G>T/A, and c.3435C>T) polymorphisms in the pharmacokinetics of oseltamivir and its active metabolite, oseltamivir carboxylate in humans. Nineteen healthy male subjects were enrolled, and their ABCB1 polymorphisms were evaluated. After the oral administration of 75 mg oseltamivir, the plasma concentrations of oseltamivir and oseltamivir carboxylate were measured. Pharmacokinetic analysis was carried out. Systemic exposure to oseltamivir and oseltamivir carboxylate was higher in the mutant group than in the wild-type and heterozygous groups. We suggest that ABCB1 polymorphisms affect the pharmacokinetics of oseltamivir in humans. Further studies in a large population are necessary to validate the results of this preliminary study (Clinical Trial Registration Information [CRIS] registry: http://cris.nih.go.kr, No. KCT0001903).
Administration, Oral
;
Humans*
;
Male
;
Oseltamivir*
;
P-Glycoprotein
;
Pharmacokinetics*
;
Plasma
8.Clinical Significance of p53, P-glycoprotein, and Glutathione S transferase-pi in Advanced Non-Small Cell Lung Cancer.
Young Don JOO ; Chang Hak SOHN
Cancer Research and Treatment 2002;34(1):34-40
PURPOSE: A retrospective study was performed o define the clninical significance of p53, P-glycoprotein (Pgp), and Glutathione S transferase-pi (GST-pi) immunohistochemical (IHC) expression in advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We reviewed fifty seven patients with advanced NSCLC who had undergone surgical resection or bronchoscopic biopsy between March 1997 and March 1999. IHC staining for p53, GST-pi, and Pgp was performed using formalin-fixed, paraffin-embedded specimens of the fifty seven patients. RESULTS: The IHC expression rate was 63% for p53, 28% for Pgp, and 53% for GST-pi, respectively. The median survival of the fifty seven patients was 45 weeks and the response rate was 38.6% (partial response, 22/57). The chemotherapy response and median survival of the p53 negative group (57% and 61 weeks) were better than those demonstrated by the p53 positive group (28% and 21 weeks) (p<0.05). Additionally, the GST-pi negative group showed a greater improvement of survival and response rate than the positive group (p<0.05). Pgp expression status appeared to have no significant differential effect on chemotherapy response and survival. CONCLUSION: These results suggest that immunohisto chemical staining of p53 and GST-pi may be useful in predicting the response to chemotherapy as well as survival in advanced NSCLC. However, this study is limited by its retrospective nature and the small numbers of tumors studied from a heterogenous group of patients.
Biopsy
;
Carcinoma, Non-Small-Cell Lung*
;
Drug Therapy
;
Glutathione*
;
Humans
;
P-Glycoprotein*
;
Retrospective Studies
9.The Multidrug Resistance-related Protein and P-glycoprotein Expressions, and the Washout Rates of 99mTc-MIBI in Infiltrating Ductal Carcinoma of Breast, Correlation with the Response After Neoadjuvant Chemotherapy.
Hi Suk KWAK ; Young Tae BAE ; Koon Taek HAN ; In Joo KIM
Journal of Breast Cancer 2007;10(1):29-35
PURPOSE: Numerous non-invasive imaging methods for evaluating the chemotherapy response of breast cancer patients are currently being explored. The aim of present study was to investigate whether the washout rates (WRs) of 99mTc-MIBI could predict the response to chemotherapy in patients suffering with infiltrating ductal carcinoma using the expressions of multidrug resistance-related protein (MRP) and P-glycoprotein (Pgp). METHODS: From May 2002 and March 2004, the patients were randomly and consecutively selected according to the results of immunohistochemical analyses of breast carcinoma specimens before the administration of neoadjuvant chemotherapy. A total 45 infiltrating ductal carcinomas in 45 female patients were selected and they were separated into three groups: group A consisted of tumors with both negative Pgp and MRP expressions (n=15); group B consisted of the tumors that were positive for either a Pgp expression or a MRP expression (n=15); group C consisted of the tumors that were positive for both Pgp and MRP expressions (n=15). All the patients were referred for double phase 99mTc-MIBI mammoscintigraphy after the injection of 925 MBq of 99mTc-MIBI to calculate the WR. The tumor response was evaluated after completion of neoadjuvant chemotherapy. The tumor response was classified as a complete or partial response (the responder group) and stable or progression (the non-responder group). All the patients underwent surgery. RESULTS: The response rate of group C was lower than that of the other groups, but the difference was not statistically significant (p=0.283). The WR of non-responder group was lower than that of the responder group, although the difference was not statistically significant (p=0.674). The washout rates of group C was the highest than other groups and the difference was statistically significant (p=0.001). CONCLUSION: In conclusion, the WR of 99mTc-MIBI is helpful for in vivo determination of both the Pgp and MRP expressions for infiltrating ductal carcinoma of the breast.
Breast Neoplasms
;
Breast*
;
Carcinoma, Ductal*
;
Drug Therapy*
;
Female
;
Humans
;
P-Glycoprotein*
10.A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.
Hyun Jung LEE ; Dae Seog HEO ; Joo Youn CHO ; Sae Won HAN ; Hye Jung CHANG ; Hyeon Gyu YI ; Tae Eun KIM ; Se Hoon LEE ; Do Youn OH ; Seock Ah IM ; In Jin JANG ; Yung Jue BANG
Cancer Research and Treatment 2014;46(3):234-242
PURPOSE: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotein, in patients with advanced cancers. MATERIALS AND METHODS: Patients with advanced solid tumors received standard therapy were given the study drug at escalating doses, using a 3+3 design. The study drug was orally administered on days 1, 8, and 15, with a 28-day cycle of administration. The dose of paclitaxel was escalated from 60 to 420 mg/m2, and the dose of HM30181A was escalated from 30-210 mg/m2. RESULTS: A total of twenty-four patients were enrolled. Only one patient experienced a dose-limiting toxicity-a grade 3 neutropenia that persisted for more than 2 weeks, at 240 mg/m2 of paclitaxel. MTD was not reached. The maximum plasma concentration was obtained at a dose level of 300 mg/m2 and the area under the curve of plasma concentration-time from 0 to the most recent plasma concentration measurement of paclitaxel was reached at a dose level of 420 mg/m2. The absorption of paclitaxel tends to be limited at doses that exceed 300 mg/m2. The effective plasma concentration of paclitaxel was achieved at a dose of 120 mg/m2. Responses of 23 patients were evaluated; 8 (34.8%) had stable disease and 15 (65.2%) had progressive disease. CONCLUSION: The study drug appears to be well tolerated, and the effective plasma concentration of paclitaxel was achieved. The recommended phase II dose for oral paclitaxel is 300 mg/m2.
Absorption
;
Humans
;
Maximum Tolerated Dose
;
Neutropenia
;
P-Glycoprotein*
;
Paclitaxel*
;
Pharmacokinetics
;
Plasma